Advicenne (ALDVI) - Net Assets
Based on the latest financial reports, Advicenne (ALDVI) has net assets worth €-24.00 Million EUR (≈ $-28.06 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.73 Million ≈ $7.87 Million USD) and total liabilities (€30.73 Million ≈ $35.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Advicenne to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-24.00 Million |
| % of Total Assets | -356.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | -682.92% |
| 10-Year Change | N/A |
| Growth Volatility | 1287.71 |
Advicenne - Net Assets Trend (2014–2024)
This chart illustrates how Advicenne's net assets have evolved over time, based on quarterly financial data. See how many days can Advicenne fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Advicenne (2014–2024)
The table below shows the annual net assets of Advicenne from 2014 to 2024. For live valuation and market cap data, see Advicenne market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-19.07 Million ≈ $-22.30 Million |
-59.34% |
| 2023-12-31 | €-11.97 Million ≈ $-13.99 Million |
-12.75% |
| 2022-12-31 | €-10.62 Million ≈ $-12.41 Million |
-3535.60% |
| 2021-12-31 | €309.00K ≈ $361.25K |
-90.56% |
| 2020-12-31 | €3.27 Million ≈ $3.83 Million |
-80.67% |
| 2019-12-31 | €16.92 Million ≈ $19.79 Million |
-42.88% |
| 2018-12-31 | €29.63 Million ≈ $34.64 Million |
-11.58% |
| 2017-12-31 | €33.51 Million ≈ $39.18 Million |
+750.57% |
| 2016-12-31 | €-5.15 Million ≈ $-6.02 Million |
-208.44% |
| 2015-12-31 | €-1.67 Million ≈ $-1.95 Million |
-192.06% |
| 2014-12-31 | €1.81 Million ≈ $2.12 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Advicenne's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2356996100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €2.46 Million | % |
| Other Comprehensive Income | €-1.00K | % |
| Other Components | €6.65 Million | % |
| Total Equity | €-19.07 Million | 100.00% |
Advicenne Competitors by Market Cap
The table below lists competitors of Advicenne ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CHARBONE HYDROGEN CORP.
F:K47
|
$18.51 Million |
|
Tungray Technologies Inc Class A Ordinary Shares
NASDAQ:TRSG
|
$18.52 Million |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
$18.53 Million |
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
$18.53 Million |
|
FAWER Automotive Parts Ltd Co
SHE:200030
|
$18.50 Million |
|
ReGen III Corp
V:GIII
|
$18.49 Million |
|
UMS Holdings Bhd
KLSE:7137
|
$18.49 Million |
|
Quince Therapeutics, Inc.
NASDAQ:QNCX
|
$18.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Advicenne's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -11,970,000 to -19,073,000, a change of -7,103,000.
- Net loss of 6,464,000 reduced equity.
- Share repurchases of 17,000 reduced equity.
- Other comprehensive income increased equity by 13,889,000.
- Other factors decreased equity by 14,511,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.46 Million | -33.89% |
| Share Repurchases | €17.00K | -0.09% |
| Other Comprehensive Income | €13.89 Million | +72.82% |
| Other Changes | €-14.51 Million | -76.08% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Advicenne's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | €0.23 | €1.09 | x |
| 2015-12-31 | €-0.26 | €1.09 | x |
| 2016-12-31 | €-0.81 | €1.09 | x |
| 2017-12-31 | €5.58 | €1.09 | x |
| 2018-12-31 | €3.72 | €1.09 | x |
| 2019-12-31 | €1.98 | €1.09 | x |
| 2020-12-31 | €0.37 | €1.09 | x |
| 2021-12-31 | €0.03 | €1.09 | x |
| 2022-12-31 | €-1.04 | €1.09 | x |
| 2023-12-31 | €-1.14 | €1.09 | x |
| 2024-12-31 | €-1.56 | €1.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Advicenne utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -129.98%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-427.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -109.74% | -107.72% | 0.57x | 1.78x | €-2.17 Million |
| 2015 | 0.00% | -3459.63% | 0.04x | 0.00x | €-3.60 Million |
| 2016 | 0.00% | -1485.07% | 0.08x | 0.00x | €-3.46 Million |
| 2017 | -13.89% | -577.29% | 0.02x | 1.15x | €-8.01 Million |
| 2018 | -15.61% | -388.68% | 0.04x | 1.12x | €-7.59 Million |
| 2019 | -83.89% | -710.20% | 0.09x | 1.35x | €-15.89 Million |
| 2020 | -453.73% | -719.98% | 0.09x | 7.34x | €-15.17 Million |
| 2021 | -4021.68% | -462.14% | 0.14x | 61.10x | €-12.46 Million |
| 2022 | 0.00% | -478.56% | 0.17x | 0.00x | €-10.42 Million |
| 2023 | 0.00% | -157.72% | 0.36x | 0.00x | €-5.83 Million |
| 2024 | 0.00% | -129.98% | 0.52x | 0.00x | €-4.56 Million |
Industry Comparison
This section compares Advicenne's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $7,882,446
- Average return on equity (ROE) among peers: -44.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Advicenne (ALDVI) | €-24.00 Million | -109.74% | N/A | $18.51 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $90.53 Million |
| Abivax SA (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.88 Billion |
| Adocia (ADOC) | $11.51 Million | 0.00% | 0.38x | $93.64 Million |
| Aelis Farma SA (AELIS) | $2.38 Million | -114.51% | 1.64x | $15.94 Million |
| Biophytis S.A. (ALBPS) | $7.01 Million | -199.64% | 2.12x | $752.91K |
| Cellectis (ALCLS) | $4.03 Million | 0.00% | 0.43x | $226.59 Million |
| Genoway (ALGEN) | $1.90 Million | 0.00% | 1.85x | $31.09 Million |
| Integragen (ALINT) | $2.17 Million | -17.27% | 3.06x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-876.00K | 0.00% | 0.00x | $1.80 Million |
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more